Last reviewed · How we verify
TETRACYCLINE
At a glance
| Generic name | TETRACYCLINE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1953 |
Approved indications
Common side effects
- Diarrhea
- Nausea
- Headache
- Abnormal feces
- Dysgeusia
- Dyspepsia
- Back pain
- Vomiting
- Tongue darkening
- Anxiety
- Gastritis
- Gastroenteritis
Serious adverse events
- Reversible neutropenia (leucopenia)
- Reversible thrombocytopenia
- QT prolongation
- Acute generalized exanthematous pustulosis (AGEP)
- Convulsive seizures
- Encephalopathy
- Aseptic meningitis
- Optic neuropathy
- Peripheral neuropathy
- Pancreatitis
Key clinical trials
- Doxycycline Use in Post-Operative Seromas (PHASE2)
- A Study of Doxycycline to Treat Chlamydial Infection (PHASE4)
- Minocycline as Adjunctive Treatment for Treatment Resistant Depression (PHASE3)
- Azithromycin Reduction to Reach Elimination of Trachoma (PHASE4)
- Optimization of Minocycline for Helicobacter Pylori Rescue Treatment (PHASE4)
- Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial (NA)
- A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity (PHASE1)
- The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |